Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, randomized, double-blind, placebo-controlled study of combination therapy doublet, PTI-808 and PTI-801

Trial Profile

A phase I, randomized, double-blind, placebo-controlled study of combination therapy doublet, PTI-808 and PTI-801

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2018

At a glance

  • Drugs PTI 808 (Primary) ; PTI-801 Proteostasis Therapeutics (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Proteostasis Therapeutics
  • Most Recent Events

    • 17 Oct 2018 According to a Proteostasis Therapeutics media release, The fourth and highest dose cohort, patients receiving PTI-801 (400 mg) and PTI-808 (300 mg), is ongoing, with data expected in the first quarter of 2019.
    • 17 Oct 2018 Preliminary results (n=21) presented in a Proteostasis Therapeutics media release.
    • 14 Mar 2018 According to a Proteostasis Therapeutics media release, initial results are expected in the middle of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top